文献速递皮肤肿瘤药疹与重症皮肤不良反应

局部应用Hedgehog抑制剂patidegib治疗Gorlin综合征的II期试验

Topical application of the Hedgehog inhibitor patidegib in patients with Gorlin syndrome: a phase II trial.
PubMed 文献 · Br J Dermatol · 2025-01-01

本研究为在英国两个中心开展的小型随机双盲IIA期试验,评估每日两次局部涂抹patidegib凝胶2%或4%于全脸及靶向BCC病灶6个月的临床与分子疗效及不良反应。事后分析提示patidegib凝胶可减少新发需手术的BCC数量并降低HH信号水平,全身药物浓度低且不良反应轻微,值得进一步临床开发。

要点

  • 局部patidegib凝胶全身吸收少,血药浓度低,肌肉痉挛和脱发等全身不良反应轻微。
  • 事后分析提示凝胶可能减少新发需手术的BCC并降低Hedgehog信号水平。
  • 结果支持进一步开展更大样本的临床研究验证其疗效与安全性。

核心结论

  • 事后分析提示patidegib局部凝胶可减少新发需手术的BCC数量并降低HH信号水平,且不良反应轻微,值得进一步临床开发。

研究设计与样本

  • 在英国两个中心开展的小型随机双盲IIA期试验,评估每日两次局部涂抹patidegib凝胶2%或4%于全脸及靶向其他部位可手术BCC共6个月的临床与分子疗效及不良反应。

主要发现

  • 事后分析提示patidegib局部凝胶减少了新发需手术的BCC数量并降低了HH信号水平。
  • 局部应用后患者血药浓度很低,不良反应轻微或没有主要不良反应。

临床怎么用

  • 对于Gorlin综合征患者,局部patidegib凝胶可能作为一种减少面部新发BCC且全身不良反应少的治疗选择,但需更多研究确认。

局限性

  • 本研究为小型IIA期试验,疗效结论基于事后分析,需更大样本研究进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with Gorlin (basal cell naevus) syndrome (GS) have numerous phenotypic abnormalities due to overactivity of the hedgehog (HH) signalling pathway, most commonly caused by a heritable mutation in PTCH1, which encodes a major inhibitor of this pathway. Oral HH inhibitors (HHi) can reverse some of the manifestations, most prominent of which is the development of numerous cutaneous basal cell carcinomas (BCCs). In order to improve the benefit-risk ratio, we developed a gel containing a small cyclopamine-derived molecule that can be applied topically in expectation that this mode of delivery can reduce the burden of BCCs without producing the systemic adverse effects that cause patients to stop oral HHi treatment. OBJECTIVES: To determine whether or not patidegib topical gel 2% or 4% can accumulate in high enough concentrations to have local anti-BCC efficacy but not so high that systemic drug levels produce the adverse effects typical of oral HHi treatment. METHODS: We conducted a small randomized double-blinded phase IIA trial at two sites in the UK, to assess the clinical and molecular efficacy and adverse effects of 6 months of twice-daily application of patidegib topical gel to the entire face, as well as to treatment-targeted surgically eligible BCCs at other anatomical sites. RESULTS: Post hoc analyses suggested that patidegib topical gel reduced the number of new, surgically eligible BCCs and the level of HH signalling, with minimal adverse effects. CONCLUSIONS: Patidegib topical gel warrants further clinical development. Gorlin syndrome is a rare genetic condition where people develop a type of skin cancer called ‘basal cell carcinoma’ (or ‘BCC’ for short), as well as other symptoms. People with Gorlin syndrome have mutations in a key regulator of what is known as ‘the Hedgehog signalling pathway’. This can lead to BCC. A drug called ‘patidegib’ inhibits this pathway. Patidegib taken orally has been shown to reduce the size of BCC tumours. In this clinical trial, patidegib was provided as a gel to be applied on the face of people with Gorlin syndrome. We did this to see whether the gel could reduce the number of new skin tumours. We aimed to find out whether applying the gel twice a day could prevent new BCC tumours on the face without causing high levels of the drug in the patient’s blood. High levels of patidegib in the blood could lead to side effects like muscle cramps and hair loss. We found that by applying patidegib as a gel, concentrations of the drug in patients’ blood were very low. Patients had minimal or no major side effects. The findings from this study suggest that patidegib gel applied to the skin could reduce the number of new BCC tumours. More studies with more patients are needed to better assess patidegib gel in treating and preventing BCC tumours in people with Gorlin syndrome.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Lear JT, Harwood CA, Hasan Z, et al. Topical application of the Hedgehog inhibitor patidegib in patients with Gorlin syndrome: a phase II trial. Br J Dermatol. 2025. PMID: 39545486. doi:10.1093/bjd/ljae444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。